Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

IGLV3-21 R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics

Ferran Nadeu, Romina Royo, Guillem Clot, Martí Duran-Ferrer, Alba Navarro, Silvia Martín, Junyan Lu, Thorsten Zenz, Tycho Baumann, Pedro Jares, Xose S. Puente, José I. Martín-Subero, Julio Delgado, Elías Campo

Blood (2021) 137 (21): 2935–2946.

https://doi.org/10.1182/blood.2020008311

Published: 2021

Includes: Supplemental data

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

Journal Articles

SOX17 Is Essential for Integration of Arterial and HOXA Programs in Hemogenic Endothelium

Ho Sun Jung, Gene I. Uenishi, PhD, Mi Ae Park, PhD, Peng Liu, PhD, Matthew Raymond, James Thomson, Irene Ong, Igor Slukvin, MD PhD

Blood (2019) 134 (Supplement_1): 2476.

https://doi.org/10.1182/blood-2019-130789

Published: 2019

Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 1755.

https://doi.org/10.1182/blood-2019-131498

Published: 2019

Journal Articles

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 4274.

https://doi.org/10.1182/blood-2019-131600

Published: 2019

Journal Articles

Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia

Yun Chen, Liguang Chen, Jian Yu, Emanuela M. Ghia, Michael Y. Choi, Ling Zhang, Suping Zhang, Elsa Sanchez-Lopez, George F. Widhopf, II, Karen Messer, Laura Z. Rassenti, Catriona Jamieson, Thomas J. Kipps

Blood (2019) 134 (13): 1084–1094.

https://doi.org/10.1182/blood.2019001366

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage

Uri Rozovski, Ping Li, PhD, David M. Harris, Zhiming Liu, Preetesh Jain, MBBS, MDDM, PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, William G. Wierda, MD PhD, Michael J. Keating, MD, Zeev E. Estrov, MD

Blood (2018) 132 (Supplement 1): 4398.

https://doi.org/10.1182/blood-2018-99-111960

Published: 2018

Journal Articles

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Thomas Kipps, MD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 4404.

https://doi.org/10.1182/blood-2018-99-117175

Published: 2018

Journal Articles

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Yun Chen, PhD, Michael Y. Choi, MD, Liguang Chen, PhD, Jian Yu, PhD, Ling Zhang, Emanuela M. Ghia, PhD, Elsa Sanchez-Lopez, PhD, George F. Widhopf II, PhD, Karen Messer, PhD, Laura Z. Rassenti, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2018) 132 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2018-99-111996

Published: 2018

Journal Articles

AML Cells Express Exclusively the Long Isoform of LEF1 and Are Highly Vulnerable to Blockage of LEF1-β-Catenin Binding

Kristin Feder, MSc, Katrin Elisabeth Edmaier-Schröger, PhD, Nicole Kirsten, PhD, Linda Geisdorf, Naidu Vegi, PhD, Klaus H. Metzeler, MD, Michaela Feuring-Buske, MD, Christian Buske, MD

Blood (2018) 132 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2018-99-116552

Published: 2018

Journal Articles

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Han Zhang, PhD, Suping Zhang, PhD, Emanuela M. Ghia, PhD, Michael Y. Choi, MD, Jieyu Zhang, MS, Liguang Chen, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 2652.

https://doi.org/10.1182/blood-2018-99-119606

Published: 2018

Journal Articles

Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1

Elsa Sanchez-Lopez, PhD, Emanuela M. Ghia, PhD, Laura Antonucci, PhD, Laura Z. Rassenti, PhD, Yun Chen, PhD, Thomas J. Kipps, MD PhD, Michael Karin, PhD

Blood (2018) 132 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2018-99-115564

Published: 2018

Journal Articles

Roring ahead with DOCK2

Andrew J. Steele

Blood (2018) 132 (2): 115–116.

https://doi.org/10.1182/blood-2018-05-848382

Published: 2018

Journal Articles

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia

Md Kamrul Hasan, Jian Yu, George F. Widhopf, II, Laura Z. Rassenti, Liguang Chen, Zhouxin Shen, Steven P. Briggs, Donna S. Neuberg, Thomas J. Kipps

Blood (2018) 132 (2): 170–178.

https://doi.org/10.1182/blood-2017-12-819383

Published: 2018

Includes: Supplemental data

Journal Articles

Wnt5a Induces ROR1 to Complex with DOCK2 and Promote Proliferation of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, PhD, Jian Yu, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Liguang Chen, PhD, Zhouxin Shen, PhD, Steven P. Briggs, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 388.

https://doi.org/10.1182/blood.V130.Suppl_1.388.388

Published: 2017

Journal Articles

PSMB9 Mediates Resistance to Bortezomib in Multiple Myeloma

Aneel Paulus, MD, Sharoon Akhtar, MPhil, Thomas Caulfield, Alak Manna, PhD, Vivek Roy, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 3836.

https://doi.org/10.1182/blood.V130.Suppl_1.3836.3836

Published: 2017

Journal Articles

Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, PhD, Jian Yu, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 389.

https://doi.org/10.1182/blood.V130.Suppl_1.389.389

Published: 2017

Journal Articles

Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway

Jian Yu, PhD, Yun Chen, PhD, Liguang Chen, PhD, Ling Zhang, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 4019.

https://doi.org/10.1182/blood.V130.Suppl_1.4019.4019

Published: 2017

Journal Articles

First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells

Mohammad Hojjat-Farsangi, MSc, PhD Assist. Prof., Amir Hossein Daneshmanesh, MD PhD, Fariba Mozaffari, MSc, PhD, Lotta Hansson, Jan Vågberg, PhD, Styrbjörn Byström, PhD, Elisabeth Olsson, PhD, Charlotta Löfberg, PhD, Charlotta Carina Norström, PhD, Johan Schultz, PhD, Martin Norin, PhD, Thomas Olin, PhD, Anders Österborg, MD PhD Prof., Ali Moshfegh, PhD, Hakan Mellstedt, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 4320.

https://doi.org/10.1182/blood.V130.Suppl_1.4320.4320

Published: 2017

Journal Articles

Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3

Yun Chen, PhD, Liguang Chen, PhD, Jian Yu, PhD, Ling Zhang, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 4282.

https://doi.org/10.1182/blood.V130.Suppl_1.4282.4282

Published: 2017

NARROW

IGLV3-21 R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

SOX17 Is Essential for Integration of Arterial and HOXA Programs in Hemogenic Endothelium

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia

Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

AML Cells Express Exclusively the Long Isoform of LEF1 and Are Highly Vulnerable to Blockage of LEF1-β-Catenin Binding

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1

Roring ahead with DOCK2

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia

Wnt5a Induces ROR1 to Complex with DOCK2 and Promote Proliferation of Chronic Lymphocytic Leukemia Cells

PSMB9 Mediates Resistance to Bortezomib in Multiple Myeloma

Wnt5a Induces ROR1 to Bind and Activate Cortactin, Which Functions in Planar Cell Polarity and Migration of Chronic Lymphocytic Leukemia Cells

Wnt5a Can Induce Activation of Rac1 and Proliferation in Mantle Cell Lymphoma Via a ROR1-Dependent, but BTK-Independent, Signaling Pathway

First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells

Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only